Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD.

ABSTRACT:

Background

This study assessed the effects of inhaled corticosteroid (ICS) on airway vascular remodeling in chronic obstructive pulmonary disease (COPD).

Methods

Thirty-four subjects with mild-to-moderate COPD were randomly allocated 2:1 to ICS or placebo treatment in a double-blinded clinical trial over 6 months. Available tissue was compared before and after treatment for vessel density, and expression of VEGF, TGF-β1, and TGF-β1-related phosphorylated transcription factors p-SMAD 2/3. This clinical trial has been registered and allocated with the Australian New Zealand Clinical Trials Registry (ANZCTR) on 17/10/2012 with reference number ACTRN12612001111864.

Results

There were no significant baseline differences between treatment groups. With ICS, vessels and angio

SUBMITTER: Soltani A 

PROVIDER: S-EPMC5038570 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature